Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.
Stelmach JE, Liu L, Patel SB, Pivnichny JV, Scapin G, Singh S, Hop CE, Wang Z, Strauss JR, Cameron PM, Nichols EA, O'Keefe SJ, O'Neill EA, Schmatz DM, Schwartz CD, Thompson CM, Zaller DM, Doherty JB. Stelmach JE, et al. Among authors: singh s. Bioorg Med Chem Lett. 2003 Jan 20;13(2):277-80. doi: 10.1016/s0960-894x(02)00752-7. Bioorg Med Chem Lett. 2003. PMID: 12482439
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
Biftu T, Scapin G, Singh S, Feng D, Becker JW, Eiermann G, He H, Lyons K, Patel S, Petrov A, Sinha-Roy R, Zhang B, Wu J, Zhang X, Doss GA, Thornberry NA, Weber AE. Biftu T, et al. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3384-7. doi: 10.1016/j.bmcl.2007.03.095. Epub 2007 Apr 2. Bioorg Med Chem Lett. 2007. PMID: 17433672
p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.
Natarajan SR, Wisnoski DD, Singh SB, Stelmach JE, O'Neill EA, Schwartz CD, Thompson CM, Fitzgerald CE, O'Keefe SJ, Kumar S, Hop CE, Zaller DM, Schmatz DM, Doherty JB. Natarajan SR, et al. Among authors: singh sb. Bioorg Med Chem Lett. 2003 Jan 20;13(2):273-6. doi: 10.1016/s0960-894x(02)00876-4. Bioorg Med Chem Lett. 2003. PMID: 12482438
Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL, Frie JL, Dixon EC, Singh SB, Choi BK, Scapin G, Fitzgerald CE, Kumar S, Nichols EA, O'Keefe SJ, O'Neill EA, Porter G, Samuel K, Schmatz DM, Schwartz CD, Shoop WL, Thompson CM, Thompson JE, Wang R, Woods A, Zaller DM, Doherty JB. Colletti SL, et al. Among authors: singh sb. J Med Chem. 2003 Jan 30;46(3):349-52. doi: 10.1021/jm025585h. J Med Chem. 2003. PMID: 12540232
SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors.
Liu L, Stelmach JE, Natarajan SR, Chen MH, Singh SB, Schwartz CD, Fitzgerald CE, O'Keefe SJ, Zaller DM, Schmatz DM, Doherty JB. Liu L, et al. Among authors: singh sb. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3979-82. doi: 10.1016/j.bmcl.2003.08.059. Bioorg Med Chem Lett. 2003. PMID: 14592489
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Biftu T, Feng D, Qian X, Liang GB, Kieczykowski G, Eiermann G, He H, Leiting B, Lyons K, Petrov A, Sinha-Roy R, Zhang B, Scapin G, Patel S, Gao YD, Singh S, Wu J, Zhang X, Thornberry NA, Weber AE. Biftu T, et al. Bioorg Med Chem Lett. 2007 Jan 1;17(1):49-52. doi: 10.1016/j.bmcl.2006.09.099. Epub 2006 Oct 5. Bioorg Med Chem Lett. 2007. PMID: 17055272
The role of tryptophan 1072 in human PDE3B inhibitor binding.
Chung C, Varnerin JP, Morin NR, MacNeil DJ, Singh SB, Patel S, Scapin G, Van der Ploeg LH, Tota MR. Chung C, et al. Among authors: singh sb. Biochem Biophys Res Commun. 2003 Aug 8;307(4):1045-50. doi: 10.1016/s0006-291x(03)01299-3. Biochem Biophys Res Commun. 2003. PMID: 12878217
803 results